Medical Condition News

RSS

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patients with heart failure with reduced ejection fraction (HFrEF) did not experience any improvement in their ability to exercise vigorously after taking the experimental heart failure drug omecamtiv mecarbil, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Leakage after left atrial appendage occlusion associated with higher risk of adverse events

Patients who had leakage to the left atrial appendage due to incomplete device sealing after left atrial appendage occlusion (LAAO) experienced more clotting and bleeding events within a year following their procedure compared with patients who had no leaking, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Smartwatch application can be used for atrial fibrillation screening

Atrial fibrillation (AFib) was confirmed in nearly 94% of people who were initially identified to have signs of the heart rhythm disorder by a smartwatch application and who followed up with a clinician, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

3 Apr 2022

The effect of COVID-19 on the lung function of young adults

Researchers evaluate whether SARS-CoV-2 infection has a negative impact on lung function in young adults who experienced mild to moderate COVID-19.

3 Apr 2022

COVID-19 vaccine can cause temporary delay in menstruation

Both the first and second doses of COVID-19 vaccines were related to a modest delay in menstruation.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Global study demonstrates some benefits of flu vaccine in people with heart failure

People with heart failure who received an annual flu shot had lower rates of pneumonia and hospitalization on a year-round basis and a reduction in major cardiovascular events during peak flu season, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Personalized nutrition education at a grocery store improves adherence to DASH diet

People who received personalized nutrition education in a series of sessions conducted at their regular grocery store significantly improved their adherence to the Dietary Approaches to Stop Hypertension (DASH) diet, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Results from a preclinical study add new evidence that a multi-mineral dietary supplement known as Aquamin could be a simple and effective way to reduce the long-term health consequences of non-alcoholic fatty liver disease.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

First practical guide on the use of digital devices for heart rhythm and rate monitoring published

Who should monitor their heart rate and rhythm and which device should they use? Find out in an international consensus document published today in EP Europace, a journal of the European Society of Cardiology (ESC) and presented at EHRA 2022, a scientific congress of the ESC.

3 Apr 2022

Recommendations to prevent, manage interference in patients with implanted cardiac devices

Recommendations on the prevention and management of interference caused by medical procedures in patients with implanted electronic cardiac devices is published today in EP Europace, a journal of the European Society of Cardiology and presented at EHRA 2022, a scientific congress of the ESC.

3 Apr 2022

Cedars-Sinai’s Los Angeles Barbershop Blood Pressure Study delivers new insights

The Los Angeles Barbershop Blood Pressure Study is delivering cutting-edge insights more than four years after the study results were published in The New England Journal of Medicine.

2 Apr 2022

New evidence on how salt reduction can benefit heart failure patients

For the past century people with weak hearts have been told to lower their salt intake, but until now there has been little scientific evidence behind the recommendation.

2 Apr 2022

High caffeine consumption induces ventricular tachyarrhythmias in rats

The Food and Drug Administration recommends healthy adults not exceed 400 milligrams (mg) of caffeine- approximately four cups of brewed coffee- a day.

2 Apr 2022

Virtual population used to replicate a clinical trial that examines kidney damage in Black Americans

Researchers have successfully used a virtual population to replicate a clinical trial that examined kidney damage in Black Americans, according to a new study at the University of Mississippi Medical Center in Jackson. John S. Clemmer, PhD, a physiologist and lead author of the study, said his team model used a calcium channel blocker to predict kidney damage.

2 Apr 2022

Medical Condition News

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Leakage after left atrial appendage occlusion associated with higher risk of adverse events

Smartwatch application can be used for atrial fibrillation screening

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

The effect of COVID-19 on the lung function of young adults

COVID-19 vaccine can cause temporary delay in menstruation

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Global study demonstrates some benefits of flu vaccine in people with heart failure

Personalized nutrition education at a grocery store improves adherence to DASH diet

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

First practical guide on the use of digital devices for heart rhythm and rate monitoring published

Recommendations to prevent, manage interference in patients with implanted cardiac devices

Cedars-Sinai’s Los Angeles Barbershop Blood Pressure Study delivers new insights

New evidence on how salt reduction can benefit heart failure patients

High caffeine consumption induces ventricular tachyarrhythmias in rats

Virtual population used to replicate a clinical trial that examines kidney damage in Black Americans

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News